For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.

Diazyme LDL-Cholesterol test kit (liquid stable), R1: 5 x 56 ml R2: 2 x 50 ml

https://www.myco-instrumentation.com/web/image/product.template/84549/image_1920?unique=c278167

Diazyme LDL-Cholesterol test kit (liquid stable), R1: 5 x 56 ml R2: 2 x 50 ml
MUST SHIP OVERNIGHT

In Stock

775.22 775.22 USD 775.22

775.22

This combination does not exist.

Get your quote in 90 minutes.
Trade in your older analyzers to recover budget.
Bundle equipment, reagents, & consumables into one cost-saving order.
Enlist our local service tech to keep uptime high.
Lower your cost per test.

Product Code: DZ128A-KY1

Manufacturer: Diazyme

Shipping Weight: 5.00lbs (2.27kg)

WHY CHOOSE MYCO INSTRUMENTATION?
See Why in 2 mins.

Diazyme LDL-Cholesterol test kit

LDL-Cholesterol test kit (liquid stable), R1: 5 x 56 ml R2: 2 x 50 ml

The Diazyme LDL-Cholesterol assay is a direct dual liquid stable reagent system which can be used reliably with fasting and non-fasting specimens. Reagent transfer is eliminated for most chemistry systems with a choice of convenient instrument specific packaging options including Roche Hitachi 917 series, Olympus AU (400/600/640/680). The assay utilizes Diazyme’s proprietary PVS\PEGME coupled technology which provides outstanding performance. The assay features a linear range of up to 250 mg/dL, intra and inter %CV values < 5.0 % and less than 10% interference from triglycerides to 1000 mg/dL, ascorbic acid to 10 mmol/L, bilirubin to 40 mg/dL, bilirubin conjugate to 30 mg/dL, hemoglobin to 1000 mg/dL. The reagent is stable for 15 months from date of certification when stored @ 2°- 8°C.


Intended use

The Diazyme LDL-Cholesterol Assay is intended for the in vitro quantitative determination of Low Density Lipoprotein Cholesterol in human serum or plasma. The reagents can assist in the diagnosis and treatment of patients at risk of developing coronary heart disease. Elevated LDL cholesterol is the primary target of cholesterol-lowering therapy.